January 28, 2023
You are here:  Home  >  Banking & Finance  >  Tri-County Public Companies  >  Earnings  >  Current Article

MannKind revenue grows but so does net loss


Revenue continued to climb for MannKind’s inhalable insulin product Afrezza, gaining 35 percent in the fourth quarter to $7.8 million, but net loss rose 46 percent to $14 million during the period. Overall in 2019, the Westlake Village biotech grew sales of Afrezza 46 percent to $25.6 million, slimming net losses by 40 percent to…


    This article is only available to Business Times subscribers
  • Subscribers: or REGISTER for complete digital access.
  • Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
  • Check the STATUS of your Subscription Account.